CJC-1295
moderate riskAlso: CJC-1295 DAC · CJC-1295 no DAC · Modified GRF 1-29
CJC-1295 is a synthetic GHRH analog stimulating GH secretion. The DAC version has ~8-day half-life. Human pharmacokinetic trials completed. Often stacked with ipamorelin for synergistic GH release. Compounding has been restricted following 2023 FDA actions.
Reported Benefits
GH stimulation
Human trials show 2–10 fold GH increases; IGF-1 elevations confirmed.
Body composition
Limited human data suggests improved lean mass and fat reduction.
Mechanism of Action
Binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH release while preserving natural rhythms.
Key Clinical Studies
Ionescu & Frohman (2006)
Phase I/II RCT · n=65
Dose-dependent GH increases sustained at 6 days post-injection (DAC formulation)
DAC vs No-DAC: Key Distinction
- With DAC: Half-life ~8 days → sustained GH elevation (“bleed”). Less pulsatile.
- Without DAC (Mod GRF 1-29): Half-life ~30 min → used with ipamorelin for amplified pulses mimicking natural GH secretion.
Combined With Ipamorelin
CJC-1295 + ipamorelin is the most common GH-axis stack. They act on different receptors (GHRH vs. ghrelin), producing synergistic GH release 2–4x greater than either alone.
Regulatory Status
RestrictedSafety Profile
Side Effects
- •Water retention
- •Carpal tunnel syndrome
- •Cortisol/prolactin elevation at high doses
- •Flushing
Contraindications
- •Active malignancy
- •Diabetic retinopathy
Drug Interactions
- •Glucocorticoids
- •Insulin
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe CJC-1295?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →